Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serostim Investigation Leads To Indictment Of Four Former Serono Execs

This article was originally published in The Pink Sheet Daily

Executive Summary

Boston U.S. Attorney's office announces indictments by a federal grand jury against two former Serono VPs and two former regional sales directors. The indictment alleges the execs conspired to offer physicians all-expenses paid trips to a meeting in Cannes, France in exchange for writing Serostim prescriptions.

You may also be interested in...



Serono Labs Pleads Guilty To Criminal Conspiracy Charges In Serostim Case

Serono Inc., which reached a $704 mil. settlement with federal and state prosecutors, says its brand products will remain available under federal healthcare programs despite the guilty plea by its U.S. affiliate.

Serono Labs Pleads Guilty To Criminal Conspiracy Charges In Serostim Case

Serono Inc., which reached a $704 mil. settlement with federal and state prosecutors, says its brand products will remain available under federal healthcare programs despite the guilty plea by its U.S. affiliate.

Serostim Sales Plan Included Physician Kickbacks, Government Alleges

A former Serono regional sales manager is charged in Boston federal court with offering kickbacks for prescribing Serostim in 1999. The Boston U.S. Attorney alleges that a Serostim sales plan “required” regional directors to target high-prescribers of the AIDS wasting treatment with “financial incentives.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel